Heat Biologics, Inc. is a biopharmaceutical company developing cellular therapeutic vaccines for cancers and infectious diseases. The company is developing the Immune Pan Antigen Cytotoxic therapy, a platform technology that delivers human cells that are reprogrammed to pump out various cancer associated antigens together with a potent immune adjuvant. The company’s products include the HS-HIV product candidate for the treatment and prevention of HIV. For more information, visit the company’s website at www.heatbio.com.